Background. Despite its widespread advocacy, shared decision making (SDM) is not routinely used for cancer screening. To better understand the implementation barriers, we describe primary care physicians' (PCPs') support for SDM across diverse cancer screening contexts. Methods. Surveys were mailed to a random sample of USA-based PCPs. Using multivariable logistic regression analyses, we tested for associations of PCPs' support of SDM with the US Preventive Service Task Force (USPSTF) assigned recommendation grade, assessed whether the decision pertained to not screening older patients, and the PCPs' autonomous v. controlled motivation-orientation for using SDM. Results. PCPs (n = 278) were, on average, aged 52 years, 38% female, and 69% white. Of these, 79% endorsed discussing screening benefits as very important to SDM; 64% for discussing risks; and 31% for agreeing with patient's opinion. PCPs were most likely to rate SDM as very important for colorectal cancer screening in adults aged 50-75 years (69%), and least likely for colorectal cancer screening in adults aged .85 years (34%).
Background. Despite its widespread advocacy, shared decision making (SDM) is not routinely used for cancer screening. To better understand the implementation barriers, we describe primary care physicians' (PCPs') support for SDM across diverse cancer screening contexts. Methods. Surveys were mailed to a random sample of USA-based PCPs. Using multivariable logistic regression analyses, we tested for associations of PCPs' support of SDM with the US Preventive Service Task Force (USPSTF) assigned recommendation grade, assessed whether the decision pertained to not screening older patients, and the PCPs' autonomous v. controlled motivation-orientation for using SDM. Results. PCPs (n = 278) were, on average, aged 52 years, 38% female, and 69% white. Of these, 79% endorsed discussing screening benefits as very important to SDM; 64% for discussing risks; and 31% for agreeing with patient's opinion. PCPs were most likely to rate SDM as very important for colorectal cancer screening in adults aged 50-75 years (69%), and least likely for colorectal cancer screening in adults aged .85 years (34%).
Regression results indicated the importance of PCPs' having autonomous or self-determined reasons for engaging in SDM (e.g., believing in the benefits of SDM) (OR = 2.29, 95% CI, 1.87 to 2.79). PCPs' support for SDM varied by USPSTF recommendation grade (overall contrast, X 2 = 14.7; P = 0.0054), with support greatest for A-Grade recommendations. Support for SDM was lower in contexts where decisions pertained to not screening older patients (OR = 0.45, 95% CI, 0.35 to 0.56). Limitations. It is unknown whether PCPs' perceptions of the importance of SDM behaviors differs with specific screening decisions or the potential limited ability to generalize findings. Conclusions. Our results highlight the need to document SDM benefits and consider the specific contextual challenges, such as the level of uncertainty or whether evidence supports recommending/not recommending screening, when implementing SDM across an array of cancer screening contexts. T he implementation of shared decision making (SDM) in practice-particularly in the context of cancer screening-remains suboptimal. [1] [2] [3] [4] [5] The clinician-reported challenges to SDM include time constraints and a perceived lack of applicability in terms of the clinical situation, patient characteristics, or both. 6 The US Preventive Services Task Force (USPSTF) and the American Cancer Society, 7, 8 while consistently advocating that clinicians use SDM when discussing cancer screening with their patients, also acknowledge the added importance of SDM when individual characteristics and personal preferences are central to determining the value of screening to a patient. Furthermore, as of February 2015, Medicare (for the first time) has mandated the use of SDM for lung cancer screening with low-dose computed tomography. 9 To our knowledge, no prior study has considered how such external pressures for SDM and the specific clinical or patient contexts impact physician support for SDM in the context of cancer screening.
Not only are the benefits of SDM underexplored empirically, 10 but there are differing levels of uncertainty regarding the balance of benefits and risks from screening across clinical contexts. This uncertainty is reflected in the recommendation grades assigned to different screenings by the USPSTF. After reviewing the strength of peer-reviewed evidence, and the balance of expected benefits and risks, the USPSTF makes a recommendation-often specific to age-and gender-defined population subgroups-as ''A'' (strongly recommends), ''B'' (recommends), ''C'' (recommendation depends on individual patient), ''D'' (recommends against), or ''I'' (insufficient evidence to recommend for or against). 11 While there has been varied support for some of the USPSTF recommendations (most notably the C recommendation for screening mammography before the age of 50 years 12 ), the USPSTF recommendations often serve as a basis for performance reporting metrics and prevention-oriented prompts and reminders. Yet, variability and uncertainty in the evidence-base underlying USPSTF recommendations reflect not only the inherent diversity of cancer screening decisions faced in primary care but also the complexities of those decisions, as patients and clinicians are expected to consider benefit/risk tradeoffs and individual risk factors, values, and preferences.
As Lègarè and others have speculated, clinicianreported barriers to SDM suggest that health professionals may decide a priori the patients or situations in which to use SDM. 6 This may be particularly true in the case of older patients where both patients and clinicians perceive barriers to older patient participation in decision making. 13, 14 In the context of cancer screening, the use of SDM among older patients may be perceived as additionally challenging, as the decision faced is often not to initiate or to discontinue regular screenings as health and life expectancy decline. Whether PCPs embrace the use of SDM in such scenarios is not known.
Further complicating the adoption of SDM may be a lack of understanding regarding what constitutes SDM. 15 As conceptualized by the USPSTF, SDM is a process in which all patients, regardless of the cancer screening decision, are involved as active partners with their clinician to clarify acceptable medical options and decide upon a preferred clinical course. 8 Yet, there is evidence to suggest that physicians may confuse SDM with counseling techniques such as motivational interviewing, action plans, or other means to encourage patients and their families to accept a clinician's recommended course of action. 16, 17 In fact, no singular, agreed upon definition of SDM exists, 18, 19 and, despite attempts at such a consensus, not even academic experts can agree on the core competencies needed to implement SDM. 20 Given the spectrum of cancer screening scenarios faced in primary care, it is becoming increasingly important to identify the factors that alter a physician's support for implementing SDM, particularly as the inherent complexities of such decisions are likely to increase with the expansion of genomics and personalized medicine. In this paper we 1) describe PCPs' beliefs regarding the importance of different communication behaviors to SDM, 2) report PCPs' support for using SDM across 11 specific cancer screening contexts, and, 3) test whether that support varies by physician characteristics, including their belief in the inherent benefit of SDM (v. external pressure to use SDM), along with characteristics pertaining to the clinical context (as characterized by the USPSTF recommendation grade), and patient context (as characterized by whether the decision is specific to not screen older patients). Given the known time constraints in primary care, particularly in relation to preventive service delivery, 21 we anticipated that PCPs may be relatively more inclined to endorse the importance of SDM when decisions are likely sensitive to individual patient preferences (i.e., grades ''C'' and ''I'') as compared with those screening contexts where the potential for benefits or risks dominate (i.e., grades ''A'' and ''D'') because of either uncertainties or similarities in the expected magnitude of the benefits and risks.
METHODS

Physician Sample and Survey Administration
The target study population was office-based PCPs practicing in the USA. In January 2015, an authorized vendor of the American Medical Association's (AMA's) Physicians Masterfile 22 identified a random sample of family medicine, general internal medicine, and general practice physicians aged 75 years or younger. We mailed a survey to 1,430 PCPs between February and May 2015 (which coincided with Medicare's initiation of coverage for lung cancer screening but preceded the formal announcement of that coverage).
The survey administration followed a modified Dillman approach. 23 We initially sent a letter of study introduction. Two weeks later, we mailed a survey packet that included a cover letter, survey booklet, pre-stamped return envelope, and a $2 bill. Two weeks later, we sent a reminder postcard to those who had yet to return the survey. Two weeks following the postcard reminder, we sent nonresponders a second survey packet. Those who completed the survey received a $10 gift card. We sent all correspondence via the US Postal Service, using first class postage stamps and personalized salutations. The Institutional Review Board of the Virginia Commonwealth University approved all aspects of the study.
Survey Content and Analytical Variables
Using a 4-point Likert response scale (i.e., not at all important, minimally important, somewhat important and very important), the survey collected information regarding respondents' support for the importance of SDM in the context of 11 specific cancer screening decisions ( Table 1 ). Four of these contexts (e.g., mammography screening among women 75 years, cervical cancer screening in previously screened women .65 years, colorectal cancer screening in adults aged 75-85 years, and colorectal screening in adults .85 years) pertain to recommendations not to screen older patients, and therefore likely to come to a decision to discontinue or not screen a patient who has previously engaged in screening.
The survey used the same 4-point Likert response scale to obtain respondents' beliefs regarding the importance of 11 communication behaviors to SDM. Behaviors assessed were adapted from those described by Makoul and Clayman 18 and included: 1) presenting screening as a choice, 2) discussing testing benefits, 3) discussing testing risks, 4) If offered, patients should understand uncertainty regarding balance of benefits/ risks eliciting patient information preferences, 5) discussing patient barriers to screening, 6) making a screening recommendation, 7) checking patient understanding of screening advantages/disadvantages, 8) discussing ''next steps,'' 9) eliciting patient preferences for decision-making involvement, 10) checking to see if screening is agreeable to patient, and 11) encouraging question asking. The PCP's underlying motivation for using SDM was assessed using 10 items from the Treatment Self-Regulation Questionnaire (TSRQ). 24 First introduced by Ryan and Connell, 25 these questions use 7-point Likert response scales to ascertain how true (i.e., not at all true to very true) a list of reasons is for why the respondent would engage in or change a behavior. The TSRQ includes six autonomous or selfdetermined reasons (e.g., I would use shared decision making with my patients because: ''I personally believe it is the best thing for my patients' health'' or ''It is important for being as good a doctor as possible'') and four controlled or externally regulated reasons (e.g., I would use shared decision making with my patients because: ''Others would be upset with me if I did not'' or ''I feel pressure from others to do so.''). The TSRQ has been validated across various health behaviors and populations 26 but, to our knowledge, has not previously been used to understand physician behavior. As is typical with the TSRQ, we constructed two variables that ranged from a score of 1 to 7: the first represented the average of responses to the six autonomous-oriented questions, and the second represented the average of responses to the four controlled-oriented questions.
The survey also ascertained PCP characteristics including age, gender, race, and practice size. Information on physician specialty (i.e., general internal medicine, family medicine) and medical school affiliation were ascertained from the AMA Physician Masterfile. 22 
Statistical Methods
We report the percentage of PCPs who endorsed each communication behavior by the level of importance endorsed. We also report the percentage who endorsed SDM by the level of importance endorsed for each of the specific cancer screening contexts. Before conducting the multivariable analyses, we collapsed Likert scale responses to ''very important'' v. other based on the overall lack of variability across responses. To evaluate the physician-and screening-context factors associated with PCPs' support for SDM, we fit multivariable logistic regression models with up to 11 repeated observations per physician (i.e., one for each of the 11 specific cancer screening decisions). This was done using generalized estimating equations (GEE) with the PROC GENMOD procedure with REPEATED statements in SAS. 27 To test the hypothesis that a PCP's likelihood of supporting SDM varied by USPSTF recommendation grade, we tested an overall contrast (using the type 3 analysis of effect X 2 available in SAS), and then, if the overall contrast was significant (P \ 0.05), tested for specific pairwise differences between recommendation grades. We also included a variable reflective of whether or not the screening decision pertained to discontinuing routine screening among older patients. Finally, the model controlled for physician-level factors, including age, gender, race, specialty, medical school/university affiliation, practice size and the PCP's autonomous and controlled regulation for using SDM.
RESULTS
Sample Characteristics
Of the 1,430 PCPs who were mailed a survey, 307 were returned, of which 278 were eligible (i.e., PCP with active office-based practice). After adjusting for ineligible cases, the survey response rate was 24%. 28 Among those sent a survey, we compared responders and non-responders in terms of age, gender, specialty, university affiliation, and practice region. We found no statistically significant differences with the exception of specialty: Those who responded to the survey were more likely to be family medicine physicians as compared with nonresponders (i.e., 58% v. 49%).
Of the sample PCPs, the mean age was 51.9 years (SD, 10.8 years); 69% were white and 38% were female. The sample was equally distributed across solo/partner practices (33%), small practices (3 to 10 physicians, 37%) and large practices (11 or more physicians, 31%), and 35% were affiliated with a medical school. The mean PCP motivation for using SDM because of its inherent benefits was 6.0 (range, 2.3 to 7.0), while the mean PCP motivation for using SDM due to external pressures was substantively lower at 2.6 (range, 1.0 to 7.0).
Physician Beliefs about Shared Decision Making Behaviors
PCPs varied in their beliefs regarding the importance of different communication behaviors to SDM SHARED DECISION MAKING AND CANCER SCREENING ORIGINAL ARTICLE (Table 2 ). For example, whereas 79% endorsed discussing the benefits of tests as very important to SDM, this was 64% for discussing the risks associated with tests. Similarly, whereas 77% endorsed encouraging patients to ask questions as very important to SDM, this was 67% for presenting screening as a choice. Fewer PCPs endorsed eliciting the patient's preferences for information (53%) as very important.
Physician Support for Shared Decision Making
When asked about the importance of SDM for cancer screening in general, 77% of respondents indicated that SDM was very important. However, when asked about the importance of SDM for specific cancer screening contexts, substantively fewer endorsed SDM as very important (Table 3) . At the high end, 69% of PCPs supported SDM as very important for colorectal cancer screening among adults aged 50 to 75 years. At the other extreme, less than half supported SDM as very important in the context of mammography screening in women aged 75 years or older (44%), cervical cancer screening in previously screened women aged 65 years or older (42%), colorectal cancer screening among adults aged 75 to 85 years (40%), and colorectal cancer screening among adults aged 85 years or older (34%). With the exception of the four scenarios that pertain to cancer screening among the aged (i.e., mammography screening among women .75 years [ As evidenced by the size of the intra-class correlation coefficient (ICC = 0.33) from the logistic regression model (Table 4) , PCPs had a tendency to be either more or less supportive of SDM regardless of clinical or patient context. However, among the PCP characteristics included in the model, none were significant except the PCP's motivation for using SDM. The more PCPs indicated they engaged in SDM because of their belief in the inherent benefits of SDM (i.e., the more they endorsed autonomous or self-determined regulation reasons for engaging in SDM), the more likely they were to support the use of SDM: for every one-point increase in a PCP's average response on the 7-point Likert scale, the PCP was more than twice as likely to support SDM as very important (Table 4) . Results from the adjusted logistic regression model further indicated that PCPs' likelihood of supporting SDM varied by USPSTF recommendation grade (type 3 analysis of effect X 2 = 14.7, P = 0.0054). Specifically, PCPs were significantly more likely to support SDM among USPSTF Grade A (strongly recommends) screening contexts compared to those contexts with other recommendation grades (Table 4 ). Among evidence grades, we also tested for each of the other pairwise comparisons, finding only a significant difference between USPSTF Grade C-recommended services and Grade D-recommended services (OR = 1.19; 95% CI, 1.00 to 1.42; data not shown). In addition, PCPs' support for using SDM was 50% less likely when the screening decision pertained to not screening older patients (Table 4 ).
DISCUSSION
Our results point to variation in PCPs' support for SDM across the diverse cancer screening contexts typically faced in primary care, and in their understanding of the behaviors important to SDM. In addition to their beliefs regarding the inherent benefits of SDM, variation in PCPs' support for SDM stems from specific characteristics of the screening contexts, such as the evidence-base underlying the screening decision and whether or not the decision pertains to the choice not to screen older patients.
Although it may be unrealistic to expect PCPs to use SDM for the delivery of all cancer screening, a priori, if PCPs were using SDM as commonly advocated, it seems reasonable to expect PCPs to endorse the importance of SDM when there is a high degree of uncertainty or when the expected balance of benefits and risks is similar and thus, when decisions are likely sensitive to individual patient preferences (i.e., recommendation Grades ''C'' and ''I''). Instead, we found that PCPs were more likely to support the importance of SDM when there was a strong and certain evidence-base that the benefits of screening outweighed the potential risks (i.e., for those screening decisions with a USPSTF A-Grade recommendation). This finding arguably makes sense in the context of colorectal cancer screening among adults aged 50 to 75 years-a screening context with an A-Grade recommendation where deciding among multiple available screening tests is considered a preference sensitive choice. However, studies have shown repeatedly that physicians infrequently offer patients a choice among available colorectal cancer screening tests defaulting to one of the available options. 29, 30 Thus, PCPs' support of SDM in this context may be also due to other factors. For example, support for SDM in the context of an A-Grade recommendation is consistent with the prior finding that physicians describe SDM as a process in which they try to convince patients to agree to a physician-preferred clinical course of action. 16 Others have suggested that physicians may feel a tension between a desire to engage patients and consider their preferences, and the need to adhere to evidence-based practice guidelines. 31, 32 We found consistently less PCP support for SDM in screening contexts where the decision was to discontinue screening among older patients rather than to initiate or continue routine screening. It may be that time pressures combined with pressures to adhere to evidence-based guidelines leave PCPs with little opportunity to raise these screening options with patients. It may also be that such conversations are uncomfortable for PCPs. Other studies have found that physicians are more likely to discuss tests with patients if they ''believe in the test and intend to order it.'' 2 Regardless of the reason, the consistent void in support for the importance of SDM in these contexts is troubling, as healthy, older adults may not receive appropriate screening and those with limited life expectancy subjected to unnecessary screening.
We found that physician beliefs regarding the inherent benefits of SDM, and not the external pressure to use SDM, are associated with PCPs' endorsement of the importance of SDM across diverse cancer screening contexts. A recent systematic review found surprisingly few evaluations of the relationship between SDM and patient outcomes in which both the decision-making process and patient outcome were empirically measured. 10 That same review found that affective-cognitive outcomes, and not behavioral and health outcomes, were most often studied and influenced by SMD. 10 Thus, although there are strong ethical and interpersonal reasons to advocate for SDM, external pressure for clinicians to use SDM may be ignored until the outcome benefits of SDM are better understood.
In the context of cancer screening, it may be important to demonstrate the outcome benefits, as PCPs are likely to feel pressure to adhere to frequently monitored, evidence-based screening recommendations, and patients rarely consider the risks associated with routine screening. 33, 34 Of particular note are our findings regarding PCPs' support for SDM in the context of lung cancer screening, which is now required by Medicare for reimbursement. 9 Despite Medicare tying a reimbursement to the documented use of SDM, we found that barely half of PCPs indicated SDM was very important in the context of lung cancer screening. It is worth noting, however, that our survey was undertaken in the four months immediately following the announcement by the Centers for Medicare and Medicaid Services, and the beliefs of PCPs may have shifted with time. Nonetheless, such findings suggest that additional training and education for providers is necessary to fully realize the benefits of SDM for lung cancer screening, a service with many potential benefits but also clear uncertainties and risks.
In addition to variable support for SDM across cancer screening contexts, we also found variable beliefs regarding the importance of many of the central SDM behaviors. While this lack of endorsement alone is of note, the patterns observed are also worthy of consideration. Clinicians were more likely to endorse the discussion of benefits as very important to SDM than they were to endorse a discussion of risks as very important. Likewise, PCPs were less inclined to endorse checking that patients understand advantages and disadvantages as very important than they were to support making a recommendation. Such findings are consistent with the idea that PCPs may view SDM as a tool to help convince patients to adhere to guideline-recommended cancer screening and may explain why it is perceived as having little value when screening is not recommended. It would be worth exploring whether PCPs' beliefs regarding the importance of these communication behaviors also vary across different cancer screening contexts.
Our results illustrate not only the need for education and training in SDM, but also the need for clinical and patient contexts to be considered within that education and training. For a more comprehensive consideration of the inherent complexities present in cancer screening, PCPs need to be willing and able to engage in SDM with their patients across a diversity of cancer screening contexts. These contexts include not only those where patient preferences should play a role in deciding among options of equal clinical effectiveness, but also those where the benefit/risk profile changes as the patient ages, the net benefit is low or unclear, or where the risks are well known. Patients often seek guidance from their physicians when deciding about cancer screening 35 and there are ongoing challenges associated with incorporating traditional decision aids into clinical practice. 36 As such, innovative tools and techniques are needed to help support these increasingly complex cancer screening decisions.
We studied only established SMD behaviors; i.e., those considered to be important to SDM by experts in the field. There may be other behaviors that PCPs believe to be important to SDM. Furthermore, we did not collect information about and therefore cannot test whether PCPs' beliefs regarding the importance of different SDM behaviors varies across specific cancer screening contexts or whether some of their reported support for SDM within a given screening context is confounded by their agreement (or disagreement) with the recommendation grade assigned by the USPSTF. In addition, our survey response rate, while comparable with other physician-based surveys, 37 and reflective of well-documented declining PCP responses to mailed surveys, 37 raises caution when generalizing findings beyond the current sample.
Contrary to our expectations that time and other constraints might lead PCPs to endorse the importance of SDM relatively more when uncertainties exist or when the balance of benefits and risks are similar, and thus when decisions are sensitive to individual patient preferences, we found PCPs most likely to endorse the importance of SDM when evidence of the benefits outweighs the risks with a high level of certainty. One plausible explanation for this finding, which is consistent with the findings of others, 16, 17 is that PCPs may equate SDM with counseling strategies that are primarily used to convince patients to adhere to guideline-recommended cancer screening. As such, our findings support ongoing concerns that the inherent complexities of cancer screening decisions are not being addressed in practice. 2, 38 For SDM to be more widely implemented, PCPs need to be able to understand the benefits of SDM and the specific communication behaviors that contribute to those benefits. Furthermore, educational and other efforts are needed to integrate SDM across diverse cancer screening contexts, including those in which evidence for screening use is weak or ambiguous.
